### Please fax both pages of completed form to your team at 888.302.1028.

To reach your team, call toll-free 844.516.3319.

You can now monitor shipments and chat online if you have questions. Go to MyAccredoPatients.com to log in or get started.

Prescription & Enrollment Form Crohn's Disease



### Four simple steps to submit your referral.

1 Patient Information		Please provide copic and prescription ins	es of front and back of all medical urance cards.
New patient Current patient		,	
Patient's first name	Last nam	e	Middle initial
Sex at birth: Male Female Pronouns			
Street address	_		
City			
Home phone			
Parent/guardian (if applicable)			
Home phone			
Alternate caregiver/contact			
Home phone			
OK to leave message with alternate caregin	•		
Patient's primary language: English O			
	•		
<b>2</b> Prescriber Information	<b>n</b> All fi	elds must be completed	d to expedite prescription fulfillment.
Date Time	Date	medication needed	
Office/clinic/institution name			
Prescriber info: Prescriber's first name		Last name	
Prescriber's title			
Office phone Fax			
Office contact and title			
Office street address			
City			
Infusion location: Patient's home Prescr			Iformation below dotted line: 
Infusion info: Infusion site name	(		
Site street address			Suite #
City			·
Infusion site contact	Phone	_ Fax	Email
3 Clinical Information			
Primary ICD-10 code (REQUIRED):	Has the	patient been treated pr	eviously for this condition? Yes No
Is patient currently on therapy? Yes No			·
Patient wt Date wt	obtained		
NKDA Known drug allergies			
Concurrent meds			

Patient's first name	Last name	Middle initial	Date of birth
Prescriber's first name	Last name	Phone	

# 4

## **Prescribing Information**

Medication	Strength/Formulation	Directions	Quantity/Refills
Amjevita™ (adalimumab- atto) Citrate Free (ADULT)	40mg/0.8mL SureClick Autoinjector 40mg/0.8mL prefilled syringe (PFS)	Starter dose:  Inject 160mg on day 1OR Inject 80mg on day 1 and day 2 followed by 80mg subcutaneously 2 weeks later (day 15) then maintenance dose starting on day 29	QS for 1 month loading dose
		Maintenance dose: Inject 40mg subcutaneously every other week	1-month supply 3-month supply Other Refills
Amjevita (adalimumabatto) Citrate Free (PEDIATRIC)  Patient weight is required for pediatric patients:	40mg/0.8mL SureClick Autoinjector 40mg/0.8mL PFS	Starter dose: For 17kg to less than 40kg: Inject 80mg subcutaneously on day 1, then 40mg administered 2 weeks later (day 15) then maintenance dose starting on day 29 For 40kg or greater: Inject 160mg day 1OR Inject 80mg each day 1 and day 2 followed by 80mg subcutaneously 2 weeks later (day 15) then maintenance dose starting on day 29	QS for 1 month loading dose
	20mg/0.4mL PFS  40mg/0.8mL SureClick Autoinjector 40mg/0.8mL PFS	Maintenance dose: For 17kg to less than 40kg:  Inject 20mg subcutaneously every other week For 40kg or greater:  Inject 40mg subcutaneously every other week	1-month supply 3-month supply Other Refills
Cimzia® (certolizumab)	Starter:  200mg/mL solution in a single-dose PFS Starter Kit 200mg/mL lyophilized powder in a single-dose vial for reconstitution	Inject 400mg subcutaneously at weeks 0, 2 and 4	1 STARTER KIT -OR- QS for full loading dose
	Maintenance:  200mg/mL solution in a single-dose prefilled syringe (PFS)  200mg/mL lyophilized powder in a single-dose vial for reconstitution	Inject 400mg subcutaneously every 4 weeks	1-month supply 3-month supply Other Refills
Other			

Dispense needles, syringes, ancillary supplies and home medical equipment necessary to administer medication.

If shipped to physician's office, physician accepts on behalf of patient for administration in office.

Prescriber's signature required (sign below) (Physician attests this is his/her legal signature. NO STAMPS)

SIGN				
HERE	Date	Dispense as written	Date	Substitution allowed

The prescriber is to comply with his/her state-specific prescription requirements such as e-prescribing, state-specific prescription form, fax language, etc. Non-compliance with state-specific requirements could result in outreach to the prescriber.

Patient's first name	Last name	Middle initial	Date of birth
Prescriber's first name	Last name	Phone	

## **4** Prescribing Information

Medication	Strength/Formulation	Directions	Quantity/Refills
Cyltezo® (adalimumab- adbm) Citrate Free (ADULT)	40mg/0.8mL pen 40mg/0.8mL PFS	Starter Dose:  Inject 160mg on day 1OR Inject 80mg on day 1 and day 2 followed by 80mg subcutaneously 2 weeks later (day 15) then maintenance dose starting on day 29	QS for 1-month loading dose
		Maintenance Dose: Inject 40mg subcutaneously every other week	1-month supply 3-month supply Other Refills
Cyltezo® (adalimumab- adbm) Citrate Free (PEDIATRIC)  Patient weight is required for pediatric patients:kg	40mg/0.8mL pen 40mg/0.8mL PFS 20mg/0.4mL PFS 40mg/0.8mL pen 40mg/0.8mL PFS	Starter Dose:  For 17kg to less than 40kg:  Inject 80mg subcutaneously on day 1, then 40mg administered 2 weeks later (day 15) then maintenance dose starting on day 29  For 40kg or greater:  Inject 160mg day 1OR- Inject 80mg on day 1 and day 2 followed by 80mg subcutaneously 2 weeks later (day 15) then maintenance dose starting on day 29  Maintenance Dose: For 17kg to less than 40kg: Inject 20mg subcutaneously every other week For 40kg or greater:	1-month supply 3-month supply Other
Humira®	Starter:	Inject 40mg subcutaneously every other week  160mg injected day 1OR	1 STARTER KIT -OR- QS
(adalimumab) (ADULT)	80mg/0.8mL prefilled pen Starter Package (3 PENS) 40mg /0.4mL prefilled syringes (PFS) for starter dose	80mg injected day 1OR 80mg injected each day 1 and day 2 followed by 80mg subcutaneously 2 weeks later (day 15) followed by maintenance dose starting on day 29	for 1 month loading dose
	Maintenance: 40mg/0.4mL citrate-free pen 40mg/0.8mL pen 40mg/0.4mL citrate-free PFS 40mg/0.8mL PFS	Inject 40mg subcutaneously every other week	1-month supply 3-month supply Other Refills
Other			

Dispense needles, syringes, ancillary supplies and home medical equipment necessary to administer medication. If shipped to physician's office, physician accepts on behalf of patient for administration in office.

Prescriber's signature required (sign below) (Physician attests this is his/her legal signature. NO STAMPS)

SIGN HERE				
HEKE	Date	Dispense as written	Date	Substitution allowed

Patient's first name	Last name	Middle initial	Date of birth
Prescriber's first name	Last name	Phone	

# 4

### **Prescribing Information**

Medication	Strength/Formulation	Directions	Quantity/Refills
Humira® (adalimumab) (PEDIATRIC)  Patient weight	Starter: 80mg/0.8mL PFS Starter Package (3 syringes) 40mg /0.4mL PFS for starter dose	160mg injected day 1OR 80mg injected each day 1 and day 2 followed by 80mg subcutaneously 2 weeks later (day 15) followed by maintenance dose starting on day 29	1 STARTER KIT -OR- QS for 1 month loading dose
is required for pediatric patients:kg	80mg/0.8mL and 40mg/0.4mL citrate-free SYRINGE starter package 40mg /0.4mL PFS for starter dose	80mg subcutaneously on day 1, then 40mg administered 2 weeks later (day 15) then maintenance dose starting on day 29.	
	Maintenance:40mg/0.4mL citrate-free pen40mg/0.8mL PFS40mg/0.4mL citrate-free PFS80mg/0.8mL citrate-free pen40mg/0.8mL pen20mg/0.2mL PFS	Inject 40mg subcutaneously every other week Inject 20mg subcutaneously every other week	1-month supply 3-month supply Other Refills
Stelara® (ustekinumab)	90mg/mL in each single-dose PFS	Maintenance: Inject 90mg subcutaneously every 8 weeks	2-month supply Other Refills
		Maintenance Dose Only Needed. If loading dose is needed, plea IV referral form. By selecting Stelara on this form, I am indicatin patient has already received/does not need IV loading dose at the	
Other			

Dispense needles, syringes, ancillary supplies and home medical equipment necessary to administer medication.

If shipped to physician's office, physician accepts on behalf of patient for administration in office.

Prescriber's signature required (sign below) (Physician attests this is his/her legal signature. NO STAMPS)

SIGN HERE	 Dispense as written	 Date	Substitution allowed
	· F · · · · · · · · · · · · · · · · · ·		

The prescriber is to comply with his/her state-specific prescription requirements such as e-prescribing, state-specific prescription form, fax language, etc. Non-compliance with state-specific requirements could result in outreach to the prescriber.

